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Abstract
Infections by influenza A viruses (IAV) are a major health burden to mankind. The current antiviral arsenal against IAV is
limited and novel drugs are urgently required. Medicinal plants are known as an abundant source for bioactive compounds,
including antiviral agents. The aim of the present study was to characterize the anti-IAV potential of a proanthocyanidin-
enriched extract derived from the aerial parts of Rumex acetosa (RA), and to identify active compounds of RA, their mode of
action, and structural features conferring anti-IAV activity. In a modified MTT (MTTIAV) assay, RA was shown to inhibit growth
of the IAV strain PR8 (H1N1) and a clinical isolate of IAV(H1N1)pdm09 with a half-maximal inhibitory concentration (IC50) of
2.5 mg/mL and 2.2 mg/mL, and a selectivity index (SI) (half-maximal cytotoxic concentration (CC50)/IC50)) of 32 and 36,
respectively. At RA concentrations.1 mg/mL plaque formation of IAV(H1N1)pdm09 was abrogated. RA was also active
against an oseltamivir-resistant isolate of IAV(H1N1)pdm09. TNF-a and EGF-induced signal transduction in A549 cells was
not affected by RA. The dimeric proanthocyanidin epicatechin-3-O-gallate-(4bR8)-epicatechin-39-O-gallate (procyanidin B2-
di-gallate) was identified as the main active principle of RA (IC50 approx. 15 mM, SI$13). RA and procyanidin B2-di-gallate
blocked attachment of IAV and interfered with viral penetration at higher concentrations. Galloylation of the procyanidin
core structure was shown to be a prerequisite for anti-IAV activity; o-trihydroxylation in the B-ring increased the anti-IAV
activity. In silico docking studies indicated that procyanidin B2-di-gallate is able to interact with the receptor binding site of
IAV(H1N1)pdm09 hemagglutinin (HA). In conclusion, the proanthocyanidin-enriched extract RA and its main active
constituent procyanidin B2-di-gallate protect cells from IAV infection by inhibiting viral entry into the host cell. RA and
procyanidin B2-di-gallate appear to be a promising expansion of the currently available anti-influenza agents.
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Introduction
Influenza A and B viruses (IAV, IBV) circulating in the human
population are responsible for seasonal epidemics of varying
extent. At present, the global annual disease burden of seasonal
influenza is estimated to be 1 billion infections, 3 to 5 million of
severe infections, and 300 000 to 500 000 fatalities. Without
doubt, vaccination remains the most important strategy for
prophylaxis and control of seasonal influenza [1]. Although
predominantly associated with mild symptoms of upper respira-
tory tract infection, the first pandemic of the 21st century caused
by IAV(H1N1)pdm09 impressively demonstrated the global health
risks associated with IAV. Ongoing zoonotic infections with avian
IAV(H5N1) and (H7N9) in the human population underscore the
permanent threat of pandemic outbreaks, of which the ‘‘Spanish
flu’’ pandemic of 1918–19 with an estimated number of 50 million
deaths world-wide has been the most devastating [2].
Two classes of antiviral drugs have been licensed for the
treatment and prophylaxis of influenza [3]. Matrix protein
inhibitors, such as amantadine and rimantadine, inhibit viral
uncoating. They are ineffective against IBV and are currently not
recommended for the treatment of IAV infections due to high
levels of resistance [4]. Neuraminidase inhibitors (NAI), such as
oseltamivir and zanamivir, inhibit the release of virus progeny
from infected cells and viral spread, are effective against IAV and
IBV and have been licensed for first-line therapy of influenza.
Although the vast majority of currently circulating IAV(H3N2)
and (H1N1)pdm09 is sensitive to oseltamivir, the wide-spread use
of oseltamivir has led to a high level of IAV(H1N1) resistance in
2008–9 [3,5]. In IAV(H1N1)pdm09 resistance against oseltamivir
is almost exclusively caused by a single amino acid exchange
(H275Y) in the neuraminidase [6]. Recently, two novel NAIs have
been approved for the treatment of influenza, peramivir and
laninamivir octanoate, the latter being effective also against
oseltamivir-resistant influenza virus strains [3,7]. Since monother-
apy with each of the NAIs currently licensed may eventually lead
to the selection of resistant virus, drug combinations directed
against different molecular targets of influenza virus may be a
promising strategy to delay the development of resistance and to
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achieve synergistic effects. Thus, novel viral targets, antiviral
agents and therapeutic strategies such as inhibitors of the viral
RNA polymerase complex and broadly neutralizing antibodies
should be developed and utilized for the treatment and
prophylaxis of influenza [8,9].
Medicinal plant extracts with anti-IAV activity have been
described in many publications [10–12]. Although in most plant-
derived preparations active compounds and structure-activity
relationships remain to be elucidated, polyphenols have been
frequently identified to be the antiviral principle in plant extracts
[13]. In particular, the broad antiviral and antimicrobial activity of
green tea and its components has received much attention [14,15].
In green tea and a number of other polyphenol-rich plant extracts,
catechins and proanthocyanidins, a subgroup of polyphenols
derived from oligomerized flavan-3-ols, were found to exert
antiviral effects against influenza viruses and other enveloped and
non-enveloped viruses [16–20]. Recently, we have shown inhibi-
tion of viral attachment of herpes simplex virus type-1 by
proanthocyanidin-enriched extracts from Rumex acetosa L.
(Polygonaceae) and Myrothamnus flabellifolia Welw. [21,22].
Extracts from R. acetosa are a component of modern phytother-
apeutical preparations with nationally registered drug status in
Europe, and are used in the treatment of acute and chronic
respiratory viral infections [23].
Aim of the present study was to investigate the anti-IAV activity
of the R. acetosa extract (RA) in vitro, to identify relevant
compounds and structural requirements for anti-IAV activity and
to characterize their mode of action. Our results show that RA
strongly inhibits growth of IAV by blocking viral entry. The
dimeric, digalloylated procyanidin epicatechin-3-O-gallate-
(4bR8)-epicatechin-39-O-gallate (syn. procyanidin B2-di-gallate)
was identified as main active principle in RA. Galloylation of the
procyanidin backbone was found to be a prerequisite for anti-IAV
activity.
Materials and Methods
Plant material, extract and isolated compounds of Rumex
acetosa
Starting materials and preparation of the Rumex acetosa L.
extract RA have been described recently [21]. Isolation and
analytical characterization of proanthocyanidins from RA have
been reported by Bicker et al. (2009) [24]. Structural features,
sources and purity of flavan-3-ols, oligomeric proanthocyanidins,
hydrolyzable tannins, depsides and building blocks of tannins used
for antiviral bioassays used in this study are given in Figure 1 and
Table 1. Sodium heparin (100,000 IU/g) was purchased from
Roth (Karlsruhe, Germany).
Cells and viruses
MDCK II cells (canine kidney cells) were propagated in
minimal essential medium (MEM; Biochrom, Berlin, Germany)
supplemented with 5% fetal calf serum (FCS; Biochrom), 2 mM L-
glutamine (Sigma-Aldrich), non-essential amino acids (16) and
100 mg/mL penicillin/streptomycin (Biochrom). A549 cells (hu-
man lung epithelial cells) were grown in DMEM (PAA Labora-
tories, Pasching, Austria), supplemented with 10% FCS and
100 mg/mL penicillin/streptomycin. Cytotoxicity, antiviral and
penetration assays (see below) were performed using serum-free
media.
The influenza A virus laboratory strain A/Puerto Rico/8/34
(PR8), and three clinical isolates of IAV(H1N1)pdm09, i.e., A/
Nordrhein-Westfalen/172/09 (NRW172), A/Nordrhein-Westfa-
len/173/09 (NRW173) [25] and isolate 1/09 (I1) obtained at the
Institute of Medical Microbiology – Clinical Virology, University
Hospital Mu¨nster, were propagated in embryonated chicken eggs.
Viral stocks were prepared as described elsewhere [26].
The number of infectious particles in viral stocks was assessed by
plaque titration. MDCK II cells were infected with serial dilutions
of IAV in PBS containing 0.21% bovine albumin (MP Biochem-
icals, Eschwege, Germany), 100 U/mL penicillin (Biochrom),
100 mg/mL streptomycin (Biochrom), 230 mmol/L MgCl2 (Roth)
and 514 mmol/L CaCl2 (Roth) for 30 min. at 37uC (500 mL/well).
After discarding the inoculum, cells were washed with PBS and
covered with 2 mL of overlay medium (MEM [Gibco, Life
Technologies, Darmstadt, Germany] containing 100 U/mL pen-
icillin, 100 mg/mL streptomycin, 0.21% NaHCO3 [Gibco], 0.01%
DEAE-dextran hydrochloride [Sigma-Aldrich], 0.21% bovine
albumin, 232 mmol/L MgCl2, 518 mmol/L CaCl2, 0.00061 %
trypsin/829 nmol/L EDTA [Biochrom] and 0.62% Avicel type
RC-591 NF [FMC BioPolymer, Philadelphia, PA, USA]). After
48 h of incubation at 37uC, overlay medium was discarded, cells
were washed with PBS, fixed with 3.7% formaldehyde for 10 min.
and stained with 0.1% crystal violet for 15 min. Subsequently,
virus plaques were counted and the infectious titer (pfu/mL) was
calculated.
Cytotoxicity assay, antiviral assays
Cytotoxicity assay. The effect of RA and its components on
the proliferation of MDCK II cells was determined in 96-well
plates (TPP, Trasadingen, Switzerland) using the MTT assay [27]
essentially as described by Gescher et al. (2011) [21] with the
exception that samples were incubated at 37uC for 1 h prior to
addition to cells and remained on the cells for 48 h. The cytotoxic
concentration of RA or its components which reduced the cells’
viability by 50% (IC50) was determined from dose-response curves.
The untreated control was arbitrarily set as 100%.
MTTIAV assay. The inhibitory effects of RA and other test
compounds on the cytopathic effect induced by IAV replication
was determined in a MDCK II cell-based assay measuring cell
viability by MTT stain (MTTIAV assay) [28]. An inoculum of
16104 pfu IAV/well (corresponding to a multi plicity of infection
of 0.1) was used to infect 96-well plates. All incubation steps were
performed with serum-free MEM. In the elementary assay, IAV
was pre-incubated with test compounds for 1 h at 37uC and
subsequently MDCK II cells were incubated with this RA/IAV
mixture for 48 h. In modified assays, either the test compound/
IAV mixture was removed from the cells after 60 min., or cells
were pre-incubated with test compounds alone for 1 h prior to
infection with IAV, or test compounds were added to the cells
following a 1 h infection period with IAV.
The antiviral activity was calculated according to the following
formula [29]:
antiviral activity (%)~
(ODT )IAV{(ODC)IAV
(ODC)mock{(ODC)IAV
x100
(ODT)IAV represents the optical density of cells, which were
infected by IAV (index: IAV) and treated with RA. (ODC)IAV
corresponds to the optical density measured for the untreated
IAV-infected cells and (ODC)mock is the optical density of
untreated, mock-infected cells. The antiviral dose of RA which
protected the cells by 50% was defined as the 50% inhibitory
concentration (IC50).
Plaque reduction assay. IAV was incubated with antiviral
compounds for 1 h at 37uC, both diluted in PBS containing
100 U/mL penicillin, 100 mg/mL streptomycin, 230 mmol/L
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MgCl2 and 514 mmol/L CaCl2. MDCK II cells, cultivated in 12-
well culture plates (Greiner Bio-One, Frickenhausen, Germany),
were washed with PBS and infected with 300 mL/well IAV/RA-
suspension (100 pfu/well). After 30 min. of incubation, the
inoculum was removed, 1 mL of overlay-medium without bovine
albumin was added and the plates were cultivated for 72 h at
37uC. Subsequently, cells were stained as described above, virus
plaques were counted and antiviral activity was calculated by the
following formula [21]:
Figure 1. Structural features of flavan-3-ols, oligomeric proanthocyanidins, hydrolyzable tannins, depsides and building blocks of
tannins tested for antiviral activity; compounds isolated from Rumex acetosa extract RA are marked by asterisk.
doi:10.1371/journal.pone.0110089.g001
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antiviral activity (%)~1{
plaque number (assay)
plaque number (control )
x100
Penetration assay. The effect of extract RA and antiviral
compounds on viral penetration was determined by a modified
plaque reduction assay. In contrast to the basic assay, cells were
treated with RA after virus attachment to the cell surface.
Penetration of IAV during the attachment and treatment phase
was prevented by strictly performing all steps at 4uC.
MDCK II cells, cultivated to 95% confluence in 12-well culture
plates, were pre-cooled to 4uC for 15 min. and washed with PBS.
600 pfu IAV, diluted in PBS (400 mL/well) containing 100 U/mL
penicillin, 100 mg/mL streptomycin, 230 mmol/L MgCl2 and
514 mmol/L CaCl2, were allowed to attach to the cells. After
20 min. the inoculum was removed, cells were washed with PBS,
PBS containing a 2-fold serial dilution of RA was added and cells
were incubated for another 30 min. at 4uC. Before shifting culture
plates to 37uC for initiation of viral penetration, cells were washed
with PBS and covered with serum-free cultivation medium (see
above). Following 30 min. incubation at 37uC, medium was
removed and cells were treated with low pH citrate buffer
(135 mM NaCl, 10 mM KCl, 40 mM citric acid, pH 3.0) for 15 s
to stop penetration and inactivate attached, non-penetrated
virions. Low pH buffer was removed by washing twice with
PBS, and overlay medium was added. Further cultivation and
quantitation of plaques was performed as described above. Mock-
treatment of attached virus and inactivation of attached mock-
treated virus by low pH citrate buffer immediately prior to the
37uC shift served as controls.
Hemagglutination inhibition test (HIT)
Twofold serial dilutions (25 mL) of test compounds in PBS and 4
hemagglutinating units (HU) of IAV (25 ml) were mixed carefully
in 96-well plates with U-shaped bottom (Thermo Fisher Scientific
Nunc, Schwerte, Germany). Plates were shaken for 5 min. and
incubated for 25 min. at room temperature (RT). 50 mL of a 1.5%
suspension of newborn chicken erythrocytes (RBC) in PBS (Labor
Dr. Merk & Kollegen, Ochsenhausen, Germany) were added, and
plates shaken again. Assays were read following a 2 h incubation
period at RT, and the minimum inhibitory concentration (MIC),
defined as the highest test compound dilution showing complete
inhibition of the agglutination of erythrocytes, was determined. In
every assay, a test compound control (compound plus RBC
without addition of IAV), and erythrocyte controls (A: IAV plus
RBC, without addition of test compound; B: RBC, without
addition of test compound or IAV) were included. Test results
were accepted if the back titration of IAV revealed 4 HU and the
controls yielded correct results.
Immunoblotting
The effect of RA or test compounds on IAV envelope proteins
was analyzed using recombinant purified HA (20 or 50 mg/mL) of
influenza virus A/California/07/2009 (H1N1) (Sino Biological,
Beijing, China). SDS-PAGE and blotting was performed essen-
tially as described earlier [21]. To detect IAV HA, membranes
were incubated with Anti-IAV H1N1 (Swine Flu 2009)
HA antibody (dilution 1: 1000; Sino Biological) or QIAexpress
Table 1. Flavan-3-ols, oligomeric proanthocyanidins, hydrolyzable tannins, depsides and building blocks of tannins tested for
antiviral activity.
no. compound source purity1 reference
1 (+)-catechin monohydrate Sigma-Aldrich, Steinheim, Germany $98%
2 (2)-epicatechin Sigma-Aldrich, Steinheim, Germany $90%
3 gallocatechin IPBP2, Mu¨nster, Germany 99% [51]
4 epigallocatechin IPBP, Mu¨nster, Germany $80% [51]
5 epicatechin-3-O-gallate IPBP, Mu¨nster, Germany $95% [24]
6 epigallocatechin-3-O-gallate Chengdu Biopurify Phytochemicals Ltd,
Chengdu, China
$95%
7 epicatechin-(4bR8)-epicatechin (procyanidin B2) IPBP, Mu¨nster, Germany 97% [24]
8 epicatechin-3-O-gallate-(4bR8)-epicatechin-39-O-gallate
(procyanidin B2-di-gallate)
IPBP, Mu¨nster, Germany 91% [24]
9 epicatechin-(4bR6)-epicatechin (procyanidin B5) IPBP, Mu¨nster, Germany 99% [24]
10 epicatechin-(4bR8)-epicatechin-(4bR8)-epicatechin (procyanidin C1) IPBP, Mu¨nster, Germany 97% [24]
11 epicatechin-(4bR8)-epicatechin-(4bR8)-epicatechin-(4bR8)-
epicatechin (procyanidin D1)
IPBP, Mu¨nster, Germany 100% [24]
12 1,2,3,4,6-penta-O-galloyl-b-D-glucose (PGG) IPBP, Mu¨nster, Germany $95% [37]
13 geraniin IPBP, Mu¨nster, Germany $95% [38]
14 corilagin IPBP, Mu¨nster, Germany $95% [38]
15 ellagic acid Roth, Karlsruhe, Germany $95%
16 rosmarinic acid Sigma-Aldrich, Steinheim, Germany 97%
17 gallic acid monohydrate Roth, Karlsruhe, Germany $97%
18 pyrogallol Merck, Darmstadt, Germany $95%
1purity was determined by quantitative HPLC (area %),
2IPBP: Institute of Pharmaceutical Biology and Phytochemistry.
doi:10.1371/journal.pone.0110089.t001
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Penta-His Antibody (dilution 1: 500; Qiagen, Hilden, Germany)
overnight.
Signal transduction assay
90–100% confluent A549 cells in 6-well culture plates were
washed with PBS and pretreated with 100 mg/mL RA for 1 h at
37uC, or left untreated. Subsequently, cells were stimulated with
EGF (30 ng/mL, 10 min.; R&D Systems, Minneapolis, MN,
USA) or TNF-a (20 ng/mL, 30 min.; Sigma-Aldrich) in the
presence of RA, or left untreated. Cells were washed with PBS
twice and lysed with radioimmunoprecipitation assay buffer
(25 mM Tris-HCl [pH 8; Roth], 137 mM NaCl [Merck], 10%
glycerol [MP Biomedicals, Illkirch, France], 0.1% SDS [Roth],
0.5% DOC [Roth], 1% octylphenoxypolyethoxyethanol [IGE-
PAL; Sigma-Aldrich], 2 mM EDTA [pH 8; Roth], 50 mM
sodium glycerophosphate [Merck Millipore, Billerica, MA,
USA], 20 mM TSPP [Roth], plus 1 tablet cOmplete mini [Roche
Diagnostics, Mannheim, Germany] per 10 mL buffer) for 45–
60 min. at 4uC. Lysates were cleared by centrifugation, and
protein content was quantified by the Bradford method. Briefly,
1 mL of 1: 5 diluted protein assay dye reagent concentrate (Bio-
Rad Laboratories, Hercules, CA, USA) was added to 5 mL
supernatant, absorption at 600 nm was determined and protein
contents were adjusted to identical levels. Protein expression was
analyzed by SDS-PAGE and immunoblot as described above. For
protein detection Anti-ERK1/2 (pT202/pY204) antibody (dilu-
tion 1: 1000; BD, Franklin Lakes, NJ, USA) or Phospho-NF-kB
p65 (Ser536)(93H1) antibody (dilution 1: 1000; Cell Signaling
Technology, Danvers, MA, USA) was employed. Loading controls
were performed with Anti-a-Tubulin (Clone DM 1A, dilution 1:
500; Sigma-Aldrich) or Anti-b-Actin (Clone AC-15, dilution 1:
1000; Sigma-Aldrich).
Statistical analysis
Data represent the means 6SD of at least three independent
experiments. Statistical significance was evaluated by a two-tailed
one sample t-test. A P value of ,0.05 indicated a statistically
significant difference.
In silico protein-ligand docking
For in silico analyses the HA of influenza virus A/California/
04/2009 (H1N1) [30] (protein data base ID 3LZG) was used. HA
of A/California/04/2009 (H1N1) is closely related to HA of the
vaccine strain A/California/07/2009 (H1N1) and HAs of
IAV(H1N1)pdm09 strains circulating in the post-pandemic era
in Europe and Asia [31,32]. Epicatechin (2), epigallocatechin-3-O-
gallate (EGCG) (6), procyanidin B2 (7) and procyanidin B2-di-
gallate (8) were docked to the HA of influenza virus in silico by the
software Molecular Operating Environment (MOE) version
2011.10 (Chemical Computing Group, Montreal, Canada). After
identifying potential binding sites at HA with the MOE module
‘‘Site Finder’’, the test compounds were docked into the 30 cavities
with the best PLB (propensity for ligand binding) score using the
MMFF946 force field as implemented in MOE. The flexible
docking method (induced fit, i.e. both the ligand and the protein
binding site were treated as flexible) was applied. The best score of
each cavity-compound pair was compared to the best score of the
remaining 29 cavities for each of the four compounds. The
docking pose represents the best geometry (lowest score) of all
investigated orientations of all compounds with respect to all
cavities taken into account.
Results and Discussion
Rumex acetosa extract RA specifically inhibits
IAV-infection in cell culture
Extract RA and its constituents were screened for anti-IAV-
activity by single cycle, MDCK II cell-based MTTIAV assay.
Depending on the IAV isolate, the screening window coefficient Z9
of the MTTIAV assay ranged from approx. 0.6 to 0.63, indicating
that this assay is well suited to detect inhibitors of IAV entry and
replication [28,33]. Extract RA exhibited 100% antiviral activity
against IAV PR8 at concentrations.5 mg/mL with an IC50 of
2.5 mg/mL. At extract concentrations$25 mg/mL a dose-depen-
dent, increasing reduction of cell vitality was observed. The CC50
of extract RA was determined to be approximately 80 mg/mL
which corresponds to a selectivity index (SI = CC50/IC50) of 32
(Figure 2A). Almost identical data were found for the clinical
isolate I1 of IAV(H1N1)pdm09 with an IC50 of 2.2 mg/mL, and a
SI of 36 (Figure 2B). The results obtained by MTTIAV assay were
corroborated by plaque reduction assay. At a concentration of
100 ng/mL extract RA reduced plaque formation of
IAV(H1N1)pdm09 I1 in a highly significant manner by 67%, at
1 mg/mL by 100% (Figure 3).
The antiviral effect of extract RA was tested in two additional
clinical isolates of IAV(H1N1)pdm09 obtained in consecutive
samples of a patient with acute respiratory distress syndrome. The
oseltamivir-sensitive isolate NRW172 was obtained early after
hospitalization, the oseltamivir-resistant isolate NRW173 was
isolated after completion of oseltamivir therapy. Extract RA
inhibited growth of NRW172 and NRW173 with similar
efficiency. The IC50 values determined for NRW172 (19 mg/
mL) and NRW173 (37 mg/mL) in MTTIAV assay were approx-
imately 10-fold higher as observed in IAV PR8 and IAV I1
(Figure 2C, D). Previous work indicated that a high protein load of
samples may reduce the antiviral activity of extract RA [22]. Since
stocks of IAV NRW172 (6.66106 pfu/mL) and NRW173
(8.36106 pfu/mL) contained significantly lower virus titers than
stocks of IAV PR8 (3.26108 pfu/mL) and I1 (3.46107 pfu/mL),
inhibitory effects of residual allantoic fluid on the anti-IAV activity
of extract RA were studied. Retesting IAV I1 diluted to
6.66106 pfu/mL in allantoic fluid of a noninfected egg led to an
approx. four-fold increase in the IC50 of extract RA (8.2 mg/mL)
(Figure S1). Thus, inhibitory effects of residual allantoic fluid on
the anti-IAV activity of extract RA appear to account for the
differences in IC50 values observed in MTTIAV assay. Accordingly,
the consistently lower IC50 values observed in plaque reduction
assay are most likely due to higher dilution of virus stocks during
incubation with extract RA. Whether strain specific factors also
determine the susceptibility of IAV to extract RA as observed for a
polyphenolic extract of Pelargonium sidoides DC [34] remains to
be clarified.
Structure-activity relationship: epicatechin-3-O-gallate-
(4bR8)-epicatechin-39-O-gallate (procyanidin
B2-di-gallate) (8) is responsible for the antiviral activity of
RA
The lead compounds in extract RA have been recently
described to be flavan-3-ols and oligomeric proanthocyanidins
[24]. To pinpoint the plant secondary products responsible for the
antiviral effect of the extract, the dominant proanthocyanidins
isolated from extract RA were tested for antiviral effects against
IAV I1 and cytotoxicity (Table 2) (for numbering of compounds
compare Table 1) at concentrations of 2, 20 and 200 mM,
respectively, by MTTIAV and cytotoxicity assay. Additionally
Procyanidins from Rumex acetosa Inhibit Attachment of Influenza Virus
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EGCG (6), a known inhibitor of IAV replication from extracts of
green tea which is not present in extract RA [17,24] was included
(Table 2).
The monomeric flavan-3-ols catechin (1) and epicatechin (2) did
not show antiviral activity. Trihydroxylation of the B-ring in
gallocatechin (3) and epigallocatechin (4) led to a slightly increased
cytotoxicity. Esterification with gallic acid also increased cytotox-
icity. Epicatechin-3-O-gallate (5) did not show antiviral activity,
while EGCG (6) exhibited strong activity at concentrations of
about 20 mM (estimated SI$17). These results indicated that an o-
trihydroxylation in the B-ring and galloylation at position O-3 is
responsible for the antiviral effects of flavan-3-ols detected by
MTTIAV assay.
Strong antiviral activity was determined for the oligomeric
proanthocyanidins in the cases where the epicatechin building
blocks are galloylated. While the dimeric epicatechin-(4bR8)-
epicatechin (procyanidin B2) (7) was inactive, the corresponding
di-galloylated procyanidin epicatechin-3-O-gallate-(4bR8)-epica-
techin-39-O-gallate (procyanidin B2-di-gallate) (8) exhibited a
prominent antiviral activity (IC50 of approx. 15 mM) with an SI
of about$13. It should be noted that the increasing cytotoxicity of
active compounds such as procyanidin B2-digallate (8) and EGCG
(6) at high concentrations reduces the extent of cytoprotection
against influenza virus detectable by MTTIAV assay. Using the
formula given in Materials and Methods to calculate the results of
Figure 2. Antiviral and cytotoxic activity of RA on MDCK II cells. 16104 pfu IAV/well in serum-free medium (antiviral activity, black bars) or
serum-free medium (cytotoxic activity, white bars) were incubated with RA at different concentrations indicated for 1 h at 37uC. 48 h after adding the
reaction mixtures to 96-well plates, the antiviral activity and cell vitality were determined by MTTIAV assay and cytotoxicity assay, respectively. The
following IAV laboratory strains and isolates were used: (A) laboratory strain PR8 [A/Puerto Rico/8/34], (B) clinical isolate I1 [A(H1N1)pdm09], (C)
clinical isolate NRW172 [A(H1N1)pdm09], (D) clinical isolate NRW173 [A(H1N1)pdm09]. Values represent mean 6SD of $3 independent experiments.
* p,0.05, ** p,0.01 (two-tailed, unpaired Student’s t-test). Statistical significance of antiviral activity was calculated for nontoxic concentrations only
(A: 1 to 10 mg/mL, B: 1 to 7.5 mg/mL, C: 1 to 25 mg/mL, D: 1 to 10 mg/mL).
doi:10.1371/journal.pone.0110089.g002
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MTTIAV assay, this seemingly reduces the antiviral activity of
active compounds at cytotoxic concentrations (200 mM) (Table 2).
Other non-galloylated di- and oligomeric procyanidins from RA
with different structural features were inactive. Compared to the
epicatechin-(4bR8)-epicatechin (procyanidin B2) (7), dimeric
epicatechin procyanidins with 4bR6-interflavan linkage such as
epicatechin-(4bR6)-epicatechin (procyanidin B5) (9) did not show
an altered antiviral profile. However, the 4bR6-linked compound
(9) exerted higher cytotoxicity compared to (7) indicating that
changes in the planarity of the molecules may significantly
influence the effects on cell physiology. The trimeric and
tetrameric procyanidins epicatechin-(4bR8)-epicatechin-(4bR8)-
epicatechin (procyanidin C1) (10) and epicatechin-(4bR8)-epica-
techin-(4bR8)-epicatechin-(4bR8)-epicatechin (procyanidin D1)
(11), respectively, offered no relevant antiviral activity but showed
weak cytotoxic effects.
Thus, within the complex mixture of extract RA dominated by
flavan-3-ols and proanthocyanidins with different degrees of
polymerization and galloylation, the antiviral activity is mostly
mediated by galloylated oligomers. The dimeric compound
procyanidin B2-di-gallate (8) was assessed as the main principle
of antiviral activity in extract RA. The content of procyanidin B2-
di-gallate (8) in extract RA was determined by UHPLC to be
0.96%. The strong antiviral effect of procyanidin B2-di-gallate (8)
was confirmed by plaque reduction assay (Figure 3). Purified
galloylated higher oligomers present in extract RA were not
available for antiviral testing, however, most likely are also active
against influenza virus. Generally, a higher number of pyrogalloyl
moieties, an increased degree of polymerization and a 4bR8
interflavan linkage amplify the anti-IAV activity of polyphenols
from extract RA. These findings are in accordance with the results
published by De Bruyne et al. (1999) [35] describing similar
structural requirements of polyphenols active against HSV and
HIV. In addition, trihydroxylation of the B-ring of non-galloylated
oligomeric proanthocyanidins has been reported to mediate anti-
influenza virus activity [34].
An insignificant anti-influenza activity of the monomeric flavan-
3-ols catechin (1) and epicatechin (2) has been reported earlier
Figure 3. Reduction of IAV plaque formation by the Rumex acetosa extract RA (A), epigallocatechin-3-O-gallate (6) (B) and
procyanidin B2-digallate (8) (C). IAV and test compounds were co-incubated for 1 h at 37uC prior to the addition to MDCK II cells. Heparin served
as positive control (D). Values (% of plaque reduction) 6SD relate to the respective mock-treated controls ( = 100%). * p,0.05, ** p,0.01 (two-tailed,
unpaired Student’s t-test).
doi:10.1371/journal.pone.0110089.g003
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[16,19]. Interestingly, Song et al. (2005) [19] showed that ECG (5)
a main constituent from green tea strongly inhibited anti-IAV and
IBV in cell culture whereas EGC (4) exhibited little antiviral
activity. Yang et al. (2014) [16] found that procyanidin B2 (7)
significantly inhibited growth of IAV. This is in contrast to our
findings where ECG (5) and procyanidin B2 (7) were screened
negative for anti-IAV activity at noncytotoxic concentrations.
Most likely, this reflects differences in the test format used, e.g.
MTTIAV assay vs. plaque reduction assay and cytopathic effect
inhibition assay, respectively. In particular, the assays used by
Song et al. (2005) [19] and Yang et al. (2014) [16] imply multi-
cycle replication of IAV and thus should also detect inhibitory
effects of compounds on late steps of the viral replication cycle,
such as assembly, maturation and release as reviewed by Beyleveld
et al. (2013) [28]. Accordingly, Song et al. (2005) [19] detected a
direct inhibition of the viral neuraminidase activity by ECG (5),
however, not by EGC (4).
A prominent virucidal activity of EGCG (6) from green tea has
been first reported by Nakayama et al. (1993) [17]. As reported for
ECG (5), EGCG (6) also directly inhibits the viral neuraminidase.
In addition to anti-influenza activity, EGCG offers broad anti-
infective properties against various viral, bacterial and fungal
pathogens as reviewed by Steinmann et al. (2012) [15].
After oral application, proanthocyanidins exhibit a very limited
bioavailability as reviewed by Zumdick et al. (2012) [36]. Thus, the
oral application of active compounds such as procyanidin B2-di-
gallate (8) for the systemic treatment of influenza virus infection
appears to be inappropriate. As an alternative, the local
application of procyanidins in the upper respiratory tract, either
by lozenges, chewing gums etc. or by inhaling devices allows the
active compounds to directly contact the virus and should be
preferred.
Because proanthocyanidins are known to have tannin-like
effects it might be assumed that these polyphenols from extract RA
nonspecifically inactivate essential viral structural proteins. There-
fore we included other polyphenols not being part of extracts from
R. acetosa, but with known strong astringent activity (Table 1).
Pentagalloyl-glucose (PGG) (12), a well characterized hydrolyzable
tannin [37], showed moderate antiviral activity, however, signif-
icant cell toxicity in the MTTIAV assay (Table 2). Also the
ellagitannins geraniin (13), corilagin (14) [38] and ellagic acid (15)
were inactive at the highest concentration tested (200 mM)
(Table 2). When added at concentrations in the millimolar range,
ellagic acid (15) has been reported to exhibit broad anti-influenza
activity in vitro and in vivo [39]. The depside rosmarinic acid (16),
known as tannin-like compound, was also inactive. Keeping in
mind that also oligomeric procyanidins such as procyanidin B2,
C1 or D1 (7, 10, 11) are known to interact strongly with proteins
in a tannin-like manner, nonspecific denaturing effects do not
appear to account for most of the antiviral activity observed for
procyanidin B2-di-gallate (8). Otherwise, a more potent activity of
the hydrolyzable tannins geraniin (13) and corilagin (14) should
have been observed. An exception appears to be PGG (12), which
exhibited moderate anti-IAV activity in MTTIAV assay with an
IC50 of 22 mM. This might be due to its flexible structure. In
contrast to geraniin (13), PGG (12) owns the capacity to rotate its
galloyl moieties relatively to the glucose. As a result PGG (12) may
be able to bind more strongly to proteins. In accordance with our
results, PGG (12) has been recently reported to possess anti-IAV
activity at micromolar concentrations and to inhibit viral entry,
budding and release [40].
Since only the galloylated compounds (6) and (8) exhibited
prominent antiviral activity, we tested the effect of free gallic acid
(17) and pyrogallol (18), mimicking a trihydroxylated phenyl
system. Both compounds, however, showed only moderate
antiviral activity yet relevant cytotoxicity at a concentration of
200 mM. Theissen et al. (2014) [41] recently reported that gallic
acid (17) inhibits reporter gene expression of the recombinant
IAV laboratory strain A/Puerto Rico/8/34-NS116-GFP in a
multi-cycle assay with an EC50 of approx. 50 mM and a SI of
approx. 15. Similar to our findings, however, preincubation of
IAV(H1N1)pdm09 particles for 2 h with 50 mg/mL (correspond-
ing to 265 mM) gallic acid (17) had only little effect on virus
replication in A549 cells. Furthermore, gallic acid (17) poorly
inhibited IAV neuraminidase with an IC50 of.500 mM. Thus, the
inhibitory mechanism of gallic acid (17) on IAV replication
remains to be clarified.
Extract RA affects viral attachment
To identify steps in the viral life cycle that were affected by
extract RA, virus and cells were treated with extract RA at
different times pre and post infection. If pre-treated IAV was
added to cells for 1 h, viral replication was inhibited completely at
concentrations of extract RA.10 mg/mL. In contrast, if cells were
infected with IAV and extract RA was added after 1 h, no
antiviral effect was observed at #10 mg/mL, indicating that
extract RA does not operate in the post-entry phase (data not
shown).
To determine whether extract RA interacts with target
molecules of the host cells or of the virus, MDCK II cells were
incubated with extract RA for 1 h and subsequently infected with
IAV. At concentrations of #10 mg/mL this preincubation of the
host cells did not result in any antiviral effects (data not shown).
This suggests that the anti-IAV activity of extract RA is caused by
direct interaction with IAV particles and inhibition of viral entry
as shown for a number of polyphenol and tannin-rich plant
extracts in earlier reports [17–19,39,41–44].
To reconnoiter the effect of extract RA to inhibit penetration of
IAV particles already attached to the cell surface we used a
penetration assay. Cells were infected at 4uC, unbound viral
particles were removed by washing, extract RA was added at 4uC
for 30 min., and penetration was allowed to occur by a
temperature shift to 37uC (30 min.) followed by washing with
pH 3.0 citrate buffer to inactivate non-penetrated virus. As shown
in Figure 4, extract RA also blocks viral penetration. However, in
comparison to incubation of IAV with extract RA prior to entry,
significantly higher concentrations of extract RA were needed to
achieve comparable antiviral effects. Washing of cells with pH 3.0
citrate buffer at 4uC immediately after the adsorption period and
prior to shifting the temperature to 37uC completely abrogated
plaque formation. These observations suggested that RA affects
virus entry primarily by inhibiting viral attachment. Similar results
were also obtained with EGCG (6) and procyanidin B2-di-gallate
(8) (Figure 4). As discussed above, the relatively high protein load
due to the presence of cells and culture media components may
increase the concentration of RA and its active constituents
needed to inhibit penetration of IAV already attached to the cell
surface. When added after the infection of MDCK cells, high
concentrations of green tea extract and EGC (4) have been
reported to affect the early phase of influenza virus infection,
possibly by interference of the polyphenolic compounds with the
acidification of endosomes [18].
RA and galloylated oligomeric procyanidins interact with
IAV hemagglutinin
Data presented above suggested that extract RA, EGCG (6) and
procyanidin B2-di gallate (8) may interfere with the sialic acid
receptor binding function of the viral HA. Therefore, effects on
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HA-mediated attachment of IAV to the cell surface were further
investigated in a hemagglutination inhibition assay. Using four
hemagglutinating units of IAV(H1N1)pdm09 I1 in allantoic fluid
(5.56107 pfu/mL) to agglutinate chicken erythrocytes, pretreat-
ment of the IAV suspension with extract RA inhibited erythrocyte
agglutination at a minimum inhibitory concentration of 156 mg/
mL (Table 3). At higher concentrations, hemagglutination reap-
peared due to direct agglutination of erythrocytes by extract RA.
By serial dilution of extract RA in PBS the minimal concentration
needed to agglutinate erythrocytes in the absence of IAV was
determined to be 156 mg/mL. Thus, treatment of IAV with
extract RA appears to directly interfere with the cell surface
receptor-binding function of IAV HA. Procyanidin B2-di-gallate
(8) did not inhibit IAV-mediated hemagglutination, however, was
able to directly agglutinate erythrocytes at a concentration$
39 mM. In accordance to Theissen et al. (2014) [41] EGCG (6)
showed no inhibitory effect on IAV-mediated hemagglutination,
however, directly agglutinated erythrocytes (Table 3). None of the
test compounds induced hemolysis (data not shown). Strong,
IAV-strain specific differences in the concentrations of EGCG
(6) needed to inhibit hemagglutination have been reported
earlier [19], and may account for the failure to detect inhibitory
effects of procyanidin B2-di-gallate (8) and EGCG (6) on
IAV(H1N1)pdm09 induced hemagglutination.
In addition, the physical interaction of extract RA and its active
compounds with recombinant, soluble HA was studied by SDS-
PAGE and immunoblotting. Incubation of HA with high
concentrations of extract RA, i.e. 2.5 to 10 mg/mL, for 1 h led
to the almost complete disappearance of the 75 – 85 kDa HA-
specific band in SDS-PAGE (Figure 5) and abrogated reactivity of
HA with an HA-specific monoclonal antibody in immunoblotting
(data not shown). Extract RA-treated HA appeared to be retained
in the gel pockets, most likely due to the formation of large,
electrophoretically immobile complexes. At lower concentrations,
i.e. 1 to 0.1 mg/mL, extract RA had no effect on the
electrophoretic mobility and immunoreactivity of HA, respective-
ly. Taking into consideration that the IAV-specific IC50 value of
extract RA in MTT and plaque reduction assay is approximately
100 to 1,000-fold lower, this finding supports the conclusion that
most of the anti-IAV activity of extract RA is not due to non-
specific tannin-like effects on viral proteins.
Incubation of HA with high concentrations of procyanidin B2-
di-gallate (8) (1.13 mM) and EGCG (6) (2.18 mM) led to a time
dependent slight reduction of the monomeric HA band and the
appearance of HA aggregates being visible in Coomassie-stained
gels as a broad 75 to.200 kDa ‘‘smear’’ (Figure 6A, C). After
incubation of HA with EGCG (6) for 4 h to 24 h a faint band
corresponding to HA dimers became visible (Figure 6A). Higher
oligomers of HA could not be detected. As compared to mock
treated HA, incubation with the galloylated oligomeric proantho-
cyanidins (6) and (8) only led to a moderate decrease in the
intensity of the band corresponding to monomeric HA in
Coomassie-stained gels (Figure 6A, C). Both compounds, however,
reduced the strength of the HA monomer-specific signal in
immunoblot (Figure 6B, D). The decrease in immunoreactivity of
HA appeared to be more pronounced for (6).
Thus, (6) and (8) exhibit tannin-like astringent effects on HA
when applied for prolonged times at high concentrations, i.e., at
concentrations approx. 100 to 10,000-fold higher than the
respective IC50 values in MTTIAV assay and plaque reduction
Figure 4. Effect of Rumex acetosa extract RA (A), epigallocatechin-3-O-gallate (6) (B) and procyanidin B2-digallate (8) (C) on the
penetration of IAV. Effects on the penetration of IAV were determined by a modified plaque reduction assay. Test compounds were added for
30 min. after attachment of IAV to MDCK II cells at 4uC. Values (% of plaque reduction) 6SD relate to the respective mock-treated controls ( = 100%)
and represent $3 independent experiments. * p,0.05, ** p,0.01 (two-tailed, unpaired Student’s t-test).
doi:10.1371/journal.pone.0110089.g004
Table 3. Effect of Rumex acetosa extract RA and single compounds on IAV-mediated hemagglutination.
compound1 MIC direct agglutination highest concentration tested
Rumex acetosa extract 156 mg/mL 156 mg/mL 10 mg/mL
epigallocatechin-3-O-gallate (6) n.d.2 156 mM 5 mM
procyanidin B2-di-gallate (8) n.d. 39 mM 5 mM
1compounds are numbered as given in Table 1,
2n.d.: not detectable.
doi:10.1371/journal.pone.0110089.t003
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assay, respectively. The observed ‘‘smear’’ in SDS-PAGE and
immunoblots may stem from HA literally coated with various
amounts of (6) and (8). This may also account for the reduced
reactivity of the His-tag-specific monoclonal antibody used to
detect recombinant soluble HA. Similar effects were observed with
an HA-specific monoclonal antibody (data not shown). The effects
of high concentrations of extract RA and its active compounds on
HA are in good accordance with the model suggested by Haslam
(1996) [45] by describing the aggregation of proteins by
polyphenols, and confirms earlier findings in HSV-1 [21]. On
the other hand, antiviral effects of (6) and (8) are detectable at
much lower concentrations. Therefore, similar to what was
observed for RA, tannin-like astringent effects are unlikely to
mediate most of the antiviral activity of these compounds.
Procyanidin B2-di-gallate (8) is predicted in silico to
interact with the sialic acid binding site of viral
hemagglutinin
To visualize the binding of components from RA to the viral
surface proteins, four selected compounds were docked to HA of
influenza virus A/California/04/2009 (H1N1) [30] in silico by
means of the software package MOE. Exemplary for the docking
results of all investigated cavities of HA, the score of the docking at
the sialic acid binding site [46] was -6.29 for procyanidin B2-di-
gallate (8), 25.55 for procyanidin B2 (7), 25.89 for EGCG (6),
and 25.28 for epicatechin (2), with (8) showing the best score. The
data demonstrated a better score of galloylated compounds in
comparison to the respective ungalloylated molecules. Addition-
ally, inspection of the best docking pose revealed the binding of (8)
(Figure 7) with both galloyl moieties and the B-ring of the second
epicatechin gallate unit deep inside the sialic acid binding pocket,
suggesting a notably stronger anchorage of galloylated molecules
in contrast to ungalloylated compounds and offering a straight-
forward explanation for the strong activity of this digalloylated
dimer. Aside from this, the investigated dimers (7) and (8) yielded a
better docking score than the monomeric (6) and (2). These results
further corroborate the observation depicted in the functional
bioassays: An increase in the degree of polymerization and
galloylation enhances the binding of proanthocyanidins to HA. As
discussed already above, these results are in contrast to a model
favoring the unspecific ‘‘coating’’ of HA by polyphenols. The
strong anchoring of the galloylated compounds (6) and (8) in the
sialic acid binding pocket of HA disclosed by in silico visualization
may block the receptor binding site of HA and consequently
specifically inhibit the viral adsorption process.
EGCG (6) blocks binding of HIV gp120 to its cellular receptor
CD4, and it has been suggested that there is an appropriate
binding site of EGCG (6) in the region of CD4 interacting with
gp120. The galloyl ring D of EGCG (6) appears to stack against
aromatic and basic amino acid side chains within the gp120
binding site of CD4, e.g., Phe 43, Arg 59, Trp62 of CD4, thereby
abrogating interaction of gp120 with CD4 [47]. Notably, crystal
structure analyses revealed that a subgroup of neutralizing
antibodies interferes with receptor binding of HA by targeting
the highly conserved Tyr98 and Trp153 at the hydrophobic cavity
base of the sialic acid binding site with an aromatic side chain
[48,49]. It is therefore worth mentioning that in our docking
model, the galloyl moiety of the second epicatechin gallate unit of
procyanidin B2-di-gallate (8) is close to the aromatic side chain of
Trp153 in the sialic acid binding pocket of HA, where it might
interact in terms of a T-shaped p-p interaction. Furthermore, the
B-ring of the second subunit is in a position where its phenolic
oxygens might form hydrogen bonds with the hydroxyl proton of
Tyr98 (both distances O…H,3 A˚; see Figure 7B).
RA does not interfere with cellular responses to TNF-a
and EGF
While the extract RA showed little cytotoxic effect over a wide
range of concentrations it might still elicit or interfere with
intracellular responses in treated cells. Thus, the effect of the
addition of high concentrations of RA (100 mg/mL) close to the
calculated CC50 for 1 h at 37uC on TNF-a and EGF induced
signal transduction was studied. As shown in Figure 8A stimula-
Figure 6. Effect of EGCG (6) (A, B) and procyanidin B2-di-
gallate (8) (C, D) on electrophoretic mobility and detection of
HA by immunoblotting. Recombinant soluble HA was either mock-
treated (lanes 1), incubated with EGCG (6) (2.18 mM) or procyanidin B2-
di-gallate (8) (1.13 mM) dissolved in PBS for the times indicated (lanes 3
to 9) or incubated with PBS only (lanes 10 to 13); EGCG (6) (2.18 mM)
and procyanidin B2-di-gallate (8) (1.13 mM) incubated in the absence of
HA served as control (lanes 2). Figure 6A, C: Coomassie-stained SDS-
PAGE. Figure 6B, D: Detection of HA by immunoblot using a penta-His-
specific monoclonal antibody. The expected position of monomeric
(approx. 75 kDa) and dimeric HA (approx. 150 kDa) is indicated.
Required parameters are missing or incorrect.
doi:10.1371/journal.pone.0110089.g006
Figure 5. Effect of RA on the electrophoretic mobility of
recombinant soluble HA. Mock-treated HA (lane 1), RA (10 mg/mL)
(lane 2), and HA treated with RA (0.1 to 10 mg/mL) as indicated for 1 h
(lanes 3 to 9) were loaded onto 10% bis-tris SDS-PAGE gels and
analyzed by Coomassie-staining. The positions of molecular weight
marker (mwm) and HA are indicated. HA conglomerates in the gel
pockets are marked by arrowhead.
doi:10.1371/journal.pone.0110089.g005
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tion of A549 cells by TNF-a led to similar increases in
phosphorylated NF-kB (pNF-kB) in RA-treated or mock-treated
cells, respectively. In the absence of TNF-a, neither RA nor mock-
treatment led to a significant induction of pNF-kB. Potential
effects of RA on Raf/MEK/ERK-signaling were investigated by
stimulation of A549 cells by EGF (Figure 8B). While non-EGF-
stimulated cells did not express pERK1/2, regardless if pretreated
with RA or not (lanes 1 and 3), EGF treatment activated its
expression (lane 2). Pretreatment of the cells with RA, followed by
stimulation with EGF did not result in a significant decrease in
pERK1/2 expression. It was thus concluded that even high
concentrations of RA close to the CC50 are unlikely to significantly
elicit or interfere with TNF-a and EGF-induced signal transduc-
tion. This is in accordance to recent results showing that cells are
inert to LADANIA067, a polyphenol-rich extract of Ribes nigrum
folium inhibiting entry of IAV [50].
Conclusions
The proanthocyanidin-enriched extract RA and its main active
constituent epicatechin-3-O-gallate-(4bR8)-epicatechin-39-O-gal-
late (procyanidin B2-di-gallate) protect cells from IAV infection by
blocking IAV adsorption and interfering with penetration at
higher concentrations. Anti-IAV-activity is dependent on galloyla-
tion of the procyanidin backbone. At effective concentrations, cells
are unaffected by RA and procyanidin B2-di-gallat. Regarding the
need for new and abundantly available anti-influenza therapeutics,
RA and procyanidin B2-di-gallate appear to be a promising
expansion of the currently available anti-influenza agents.
Supporting Information
Figure S1 Inhibitory effect of residual allantoic fluid on the
antiviral activity of RA. To demonstrate that titres of viral stocks
prepared from allantoic fluid of infected eggs have an impact on
the outcome of the MTTIAV assay, stocks of isolate I1
(H1N1)pdm09 were approx. 50-fold prediluted in allantoic fluid
(from 3.26108 pfu/mL to 6.66106 pfu/mL). Subsequently, virus
was diluted to 16104 pfu IAV/well in serum-free medium and the
antiviral activity and cell vitality were determined by MTTIAV
assay and cytotoxicity assay, respectively (compare Figure 2).
Values represent mean 6SD of $3 independent experiments,
* p,0.05, ** p,0.01 (two-tailed, unpaired Student’s t-test).
Statistical significance of antiviral activity was calculated for
nontoxic concentrations only (1 to 5 mg/mL).
(TIF)
Figure 7. Protein-ligand docking of epicatechin-3-O-gallate-
(4bR8)-epicatechin-39-O-gallate (8) into the sialic acid binding
cavity of hemagglutinin. (A) 3D model; protein: green: hydrophobic,
purple: polar, red: exposed; ligand: yellow: carbon, light grey: hydrogen,
red: oxygen, blue: nitrogen; (B) Interactions of Tyr98 and Trp153; (C) 2D.
doi:10.1371/journal.pone.0110089.g007
Figure 8. Influence of extract RA on TNF-a (A) and EGF (B)
induced signal transduction in A549 cells. Lanes 1 and 2 represent
cells preincubated for 1 h with medium, lanes 3 and 4 with RA (100 mg/
mL). (A) Stimulation of cells with TNF-a (20 ng/mL, 30 min.) (lane 2, 4),
and detection of phosphorylated NF-kB; loading control b-actin; (B)
stimulation of cells with EGF (30 ng/mL, 10 min.) (lane 2, 4), and
detection of phosphorylated ERK1/2; loading control a-tubulin.
doi:10.1371/journal.pone.0110089.g008
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